Abstracts of the 13th Central European Lung cancer Conference, June 24-27, 2012, Prague, Czech RepublicPETRUZELKA, Lubos; ZEMANOVA, Milada.Lung cancer. 2012, Vol 77, issn 0169-5002, 49 p., SUP1Conference Proceedings

Abstracts of the 10th Central European Lung Cancer Conference, June 18-21, 2006, Prague, Czech RepublicZATLOUKAL, Petr; PETRUZELKA, Luboš.Lung cancer. 2006, Vol 52, issn 0169-5002, 52 p., SUP2Conference Proceedings

Adenocarcinoma of the lung among women: risk associated with smoking, prior lung disease, diet and menstrual and pregnancy historyZATLOUKAL, Petr; KUBIK, Antonin; PAUK, Norbert et al.Lung cancer. 2003, Vol 41, Num 3, pp 283-293, issn 0169-5002, 11 p.Article

Breast cancer risk assessment in the Czech female population : an adjustment of the original Gail modelNOVOTNY, Jan; PECEN, Ladislav; PETRUZELKA, Lubos et al.Breast cancer research and treatment. 2006, Vol 95, Num 1, pp 29-35, issn 0167-6806, 7 p.Article

The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech RepublicKLEIBL, Zdenek; NOVOTNY, Jan; BEZDICKOVA, Drahomira et al.Breast cancer research and treatment. 2005, Vol 90, Num 2, pp 165-167, issn 0167-6806, 3 p.Article

A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancerDITTRICH, Christian; PETRUZELKA, Lubos; VODVARKA, Pavel et al.Clinical cancer research. 2006, Vol 12, Num 23, pp 7071-7078, issn 1078-0432, 8 p.Article

Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized studyZATLOUKAL, Petr; PETRUZELKA, Lubos; ZEMANOVA, Milada et al.Lung cancer. 2004, Vol 46, Num 1, pp 87-98, issn 0169-5002, 12 p.Article

Sentinel Lymph Node Biopsy in Breast Cancer Patients Treated With Neoadjuvant ChemotherapyPECHA, Vaclav; KOLARIK, Dusan; KOZEVNIKOVA, Renata et al.Cancer. 2011, Vol 117, Num 20, pp 4606-4616, issn 0008-543X, 11 p.Article

Assessment of In vitro drug resistance of human breast cancer cells subcultured from biopsy specimensKRASNA, Luboslava; NETIKOVA, Irena; CHALOUPKOVA, Alena et al.Anticancer research. 2003, Vol 23, Num 3B, pp 2593-2599, issn 0250-7005, 7 p.Article

Role of taxanesPETRUZELKA, Lubos.Breast cancer research and treatment. 2003, Vol 81, pp S17-S24, issn 0167-6806, SUP1Conference Paper

Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM TrialDI LEO, Angelo; JERUSALEM, Guy; PENDERGRASS, Kelly et al.Journal of the National Cancer Institute. 2014, Vol 106, Num 1, issn 0027-8874, 337.1-337.7Article

Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trialZATLOUKAL, Petr; PETRUZELKA, Lubos; HORENKOVA, Eva et al.Lung cancer. 2003, Vol 41, Num 3, pp 321-331, issn 0169-5002, 11 p.Article

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodologyGARNETT, Sally Anne; MARTIN, Miguel; LICHINITSER, Mikhail R et al.Breast cancer research and treatment. 2013, Vol 138, Num 1, pp 149-155, issn 0167-6806, 7 p.Article

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast CancerDI LEO, Angelo; JERUSALEM, Guy; PENDERGRASS, Kelly et al.Journal of clinical oncology. 2010, Vol 28, Num 30, pp 4594-4600, issn 0732-183X, 7 p.Article

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialDAVIES, Christina; HONGCHAO PAN; BRADBURY, Joan et al.Lancet (British edition). 2013, Vol 381, Num 9869, pp 805-816, issn 0140-6736, 12 p.Article